Prophylactic treatment improves outcomes in pediatric patients with high-risk hematological malignancies, suggesting its effectiveness.
These data suggest that prophylactic DLI may represent a safe and effective treatment option for pediatric patients with hematological malignancies at high risk of posttransplant relapse.
No takes yet. Share an insight, caveat, or question.
Epple et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: